Lensar - W/I | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 13.94 M

Revenue: As of FY2025 Q2, the actual value is USD 13.94 M, missing the estimate of USD 16.55 M.

EPS: As of FY2025 Q2, the actual value is USD -0.15, missing the estimate of USD -0.075.

EBIT: As of FY2025 Q2, the actual value is USD -862 K.

Segment Revenue

• Total Revenue: For the quarter ended June 30, 2025, total revenue was $13.9 million, a 10% increase from $12.6 million in the same quarter of 2024. This increase was primarily driven by a 23% rise in worldwide procedure volume.
• System Revenue: Revenue from system sales was $2.576 million, slightly down from $2.654 million in the same period of 2024.
• Recurring Revenue: Total recurring revenue, which includes procedure, lease, and service revenues, was $11.359 million, up from $9.982 million in the second quarter of 2024.

Operational Metrics

• Net Loss: The net loss for the quarter was - $1.8 million, or - $0.15 per common share, compared to a net loss of - $9.0 million, or - $0.79 per common share, in the same quarter of 2024. The reduction in net loss was mainly due to changes in warrant liability.
• Operating Loss: Operating loss for the quarter was - $6.289 million, compared to - $5.280 million in the second quarter of 2024.
• EBITDA: EBITDA for the quarter was - $0.9 million, compared to - $8.3 million in the same period of 2024. Adjusted EBITDA was - $0.3 million, compared to $30,000 in the second quarter of 2024.

Cash Flow

• Cash and Cash Equivalents: As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $20.3 million, down from $22.5 million as of December 31, 2024.

Unique Metrics

• ALLY Systems: 18 ALLY Robotic Cataract Laser Systems were placed in the second quarter of 2025, with an additional backlog of 18 systems pending installation. The installed base of ALLY Systems grew by 107% compared to the second quarter of 2024.

Outlook / Guidance

• The company expects the proposed merger with Alcon to close by the end of the year, pending regulatory approvals. The merger was overwhelmingly approved by stockholders, with over 99% of votes in favor.